Dr. Park on Considerations of CAR T-Cell Therapy in Relapsed/Refractory ALL

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses considerations for CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia (ALL).

Several factors should be taken into account when considering CAR T-cell therapy for patients with ALL, says Park.

​Patients should be consulted early on regarding their eligibility for CAR T-cell therapy, ​Park explains. Then, optimizing bridging therapy ​is necessary to ensure patients have the best chance of deriving benefit from CAR T-cell therapy. 

Patients are encouraged to reach out regarding any questions they may have as a lot of preparation is involved ​prior to CAR T-cell administration, Park explains. 

In addition, clinical trials can be recommended to eligible patients​ as ALL remains a rare disease, Park concludes.